NewLink Genetics Announces Exclusive Worldwide Licensing Agreement For Development Of NLG919, An IDO Inhibitor In Phase 1, And Research Collaboration For The Discovery Of Next Generation IDO/TDO Inhibitors
October 20, 2014 at 07:01 AM EDT
NewLink Genetics Corporation (Nasdaq: NLNK), a biopharmaceutical company focused on discovering, developing, and commercializing novel ...
